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Abstract 
Rationale: Data from animal models of hypertension indicate that high blood pressure may 
develop as a vital mechanism to maintain adequate blood flow to the brain. We propose that 
congenital vascular variants of the posterior cerebral circulation and cerebral hypoperfusion 
could partially explain the etiology of essential hypertension, which remains enigmatic in 95% of 
patients.  
 
Methods and Results: To evaluate the role of the cerebral circulation in the pathophysiology of 
hypertension, we completed a series of retrospective and mechanistic case-control magnetic 
resonance imaging and physiological studies, in normotensive and hypertensive humans 
(n=259). Interestingly, in humans with hypertension, we report a higher prevalence of congenital 
cerebrovascular variants; vertebral artery hypoplasia and an incomplete posterior circle of Willis, 
which were coupled with increased cerebral vascular resistance, reduced cerebral blood flow 
and a higher incidence of lacunar type infarcts. Causally, cerebral vascular resistance was 
elevated before the onset of hypertension and elevated sympathetic nerve activity (n=126). 
Interestingly, untreated hypertensive patients (n=20) had a cerebral blood flow similar to age-
matched controls (n=28). However, participants receiving anti-hypertensive therapy (with blood 
pressure controlled below target levels) had reduced cerebral perfusion (n=19). Finally, elevated 
cerebral vascular resistance was a predictor of hypertension suggesting it may be a novel 
prognostic and/or diagnostic marker (n=126).   
 
Conclusions: Our demonstration that brain blood flow is a major factor in triggering 
hypertension means that lowering blood pressure may worsen cerebral perfusion in susceptible 
individuals. Thus, cerebrovascular architecture may need to be considered in the prognosis, 
diagnosis and treatment of hypertension. 
 
 
Key words: Hypertension, vertebral artery hypoplasia, cerebral blood flow, sympathetic nerve 
activity, and magnetic resonance imaging  
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Abbreviations 
 
ANCOVA; analysis of covariance 
BMI; body mass index 
BOLD; blood oxygen level dependant 
DBP; diastolic blood pressure 
CoW; circle of Willis 
MRI; magnetic resonance imaging 
MRA; magnetic resonance angiography 
MSNA; Muscle sympathetic nerve activity 
NHS; National Health Service 
SBP; systolic blood pressure 
SNA; sympathetic nerve activity 
PCASL; pseudo continuous arterial spin labelling 
RVLM; rostral ventrolateral medulla 
TE; echo time 
TR; repetition time 
VAH; vertebral artery hypoplasia 
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Introduction 
High blood pressure affects ~25% of the world’s population and is the largest single contributor 
to global mortality 1. Hypertension represents a significant economic burden to public healthcare 
providers, where the global cost of non-optimal blood pressure is estimated to be US$370 billion 
(10% of healthcare expenditure) 2. Remarkably, despite the availability of many pharmacological 
treatments, blood pressure is poorly controlled with a recent report stating that only 53% of 
patients prescribed anti-hypertensive medication have blood pressure controlled 3. This reflects 
the well-known heterogeneity of the syndrome including epigenetic and inherited factors 
contributing to the unknown causes in 95% of patients 4.  
 
Despite the devastating consequences of hypertension (e.g. stroke, kidney failure, coronary 
heart disease, death 1, 2), the mechanisms that lead to the onset of hypertension in humans are 
poorly understood. It is well established that elevated sympathetic nerve activity (SNA) 
contributes to the development of hypertension in most humans 5-7 but what initiates this 
remains unclear. Experimental data from hypertensive rats and observations in post-mortem 
human studies suggest that blood flow to the brain might be important in setting the operating 
level of SNA and thus systemic arterial pressure 8, 9.   Evidence from Dickinson 10 showed that 
the vertebral arteries in hypertensive patients were narrower than those observed in 
normotensive individuals. Dickinson and Thomson 9 demonstrated that high vertebral artery 
resistance correlated with higher blood pressure; importantly, a weaker relationship was found 
in other arteries including femoral, renal and internal carotid arteries. They proposed that 
narrowing of the vertebral arteries with subsequent brainstem hypoperfusion might be a cause 
of hypertension, rather than being a consequence, but had no evidence to support causality. 
This has been termed “Cushing’s mechanism” or “the selfish brain hypothesis” of hypertension 
11. The mechanism may trigger elevations in SNA and blood pressure thereby maintaining 
cerebral blood flow 8, 12. Evidence from spontaneously hypertensive rats at a pre-hypertensive 
age supports this notion: Cates et al. 8 demonstrated that vertebrobasilar artery hypertrophy 
occurred before the onset of hypertension in these animals. The authors also showed that 
brainstem ischemia caused by bilateral vertebral artery clamping, generated a greater increase 
in SNA in pre-hypertensive spontaneously hypertensive rats compared to age-matched 
normotensive animals8. Additionally, the brainstem of hypertensive rats is hypoxic and this is 
accentuated when blood pressure is normalised 13.  
 
We have addressed the issue of whether “Cushing’s mechanism” is involved in the development 
of hypertension in humans. This may have a significant impact on the diagnosis and treatment 
of hypertension, whilst potentially aiding prevention of early onset vascular dementia in 
hypertensive humans14. Thus, we have evaluated the temporal relationship of changes in 
cerebral vascular structure and cerebral blood flow with both the onset of hypertension and 
raised SNA in humans. We performed a series of retrospective and mechanistic case-control 
studies in a range of participants with different levels of blood pressure and classifications of 
hypertension.  Uniquely, we show that congenital cerebral vascular variants, vascular resistance 
and blood flow are tightly coupled to the development of hypertension in humans.  
 
Methods 
Retrospective study 
We first measured whether there were anatomical differences in the cerebral circulation of 
hypertensive patients compared to controls. We specifically focused on vertebral artery 
hypoplasia (VAH; a congenital anatomical variant of the posterior circulation that occurs in the 
general population), which is associated with lower posterior cerebral territory blood flow 15, and 
variations in the anatomy of the circle of Willis (CoW). We hypothesised that the occurrence of 
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anatomical variants in the vertebral arteries and CoW would be higher in the hypertensive 
population compared to that reported for healthy controls.  
 
Study population 
133 patients with essential hypertension referred to the Bristol Heart Institute tertiary 
hypertension clinic between February 2012 and April 2015 were included in the retrospective 
analyses (secondary causes of hypertension had been excluded in clinic). The local Research 
Ethics committee confirmed that the study conformed to the governance arrangements for 
research ethics committees. All patients provided written informed consent. Supplementary 
Table 1 shows patient characteristics. Cases included were from consecutive referrals by the 
hypertension clinic to the Cardiovascular Magnetic Resonance Unit in the NIHR Bristol 
Cardiovascular Biomedical Research Unit in the Bristol Heart Institute.  
 
Blood pressure measurements 
Average office systolic (SBP) and diastolic blood pressures (DBP) were measured from both 
arms after seated rest, using standard automated sphygmomanometry with an appropriate 
sized cuff 16. In a subgroup of patients (n= 84), 24 hour ambulatory blood pressure monitoring 
was completed 17 (Supplementary Table 1).  
 
MRI procedures 
3D time-of-flight MR angiography (MRA) at 1.5T (Avanto, Siemens, Erlangen, Germany) with a 
dedicated head coil was used to measure arterial anatomy (TR = 38ms, TE= 5.28ms, flip angle 
= 25 degrees, voxel size = 0.7 x 0.5 x 0.8mm, field of view = 200mm, covering major arteries 
feeding into the CoW). See supplementary material for further information regarding angiogram 
analyses.  
 
Briefly, scans were routinely reported by a Consultant Radiologist and retrospectively reviewed 
blindly by a Radiologist with >6 years’ experience. The visualised V2, V3 and V4 segments were 
analysed. Vertebral artery hypoplasia was defined as a diameter <2 mm uniformly throughout 
the vessel, and not if only a focal narrowing was presented suggestive of atherosclerotic steno-
occlusive disease, as previously described 15. CoW anatomy was reviewed as previously 
described 18. In summary, vessels that were visualised as continuous segments of at least 0.8 
mm in diameter were considered present and those smaller than 0.8 mm in diameter were 
considered hypoplastic. VAH was compared to data previously reported from 306 healthy 
controls 15. CoW morphology was classified according to normal reference standards 18.  
 
Case-control study 
Participants 
Following approval by NHS Research Ethics Committee (11/SW/0207) and local R&D approval, 
142 participants were prospectively recruited and enrolled at a single site (University Hospitals 
Bristol NHS Trust and Foundation). Participants gave their written informed consent to 
participate in this study. 16 volunteers were excluded due to screen failure and/or early 
termination of MRI scan due to discomfort or unforeseen technical difficulties. See 
supplementary material for inclusion and exclusion criteria. Table 1 outlines participant 
characteristics and the number and classes of anti-hypertensive medications being taken.  One 
patient in this study had received renal denervation, which was successful in treating their 
hypertension. 
 
Six specific blood pressure subgroups were prospectively recruited: young normotensive (age 
<35 years; Table 2 for characteristics), older normotensive (age >35 years), borderline/pre-
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hypertensive, untreated hypertensive, treated-controlled hypertensive (taking anti-hypertensive 
medication and blood pressure controlled), and treated-uncontrolled hypertensive groups 
(taking anti-hypertensive medications, but blood pressure is uncontrolled). Borderline 
hypertension was defined as an office blood pressure 135-140/85-90 mmHg and a daytime 
ambulatory blood pressure 130-135/80-85 mmHg.  
 
Screening blood pressures 
Participants attended a screening session, where office blood pressure was measured using an 
automated cuff (Omron, The Netherlands), in line with the European Society of Hypertension 
guidelines 19. Participants were fitted with an ambulatory blood pressure monitor (Spacelabs, 
OSI Systems Company, USA). Their 24-hour blood pressure was measured twice per hour 
during the daytime and once per hour during the night.  
 
Microneurography 
Peroneal microneurography was completed to measure multi-unit muscle sympathetic nerve 
activity (MSNA). For full methods, see supplementary material. Following instrumentation, 5-10 
minutes of baseline data were collected in all patients. Heart rate, blood pressure and MSNA 
were measured and recorded continuously using a data acquisition program on a study laptop 
(LabChart, AD instruments). MSNA was quantified as bursts/100 heartbeats and bursts/min by 
blinded investigators, using a semi-automated script (Spike 2, Cambridge Electronic Designs).   
 
MRI acquisition 
All study participants were scanned using 3T MRI (GE HDx, Milwaukee, Wisconsin, USA).  The 
protocol consisted of a high resolution T1-weighted fast spoiled gradient echo (3D-FSPGR) 
structural scan, 3D time of flight angiography to measure arterial anatomy, phase contrast pulse 
sequences to measure blood flow in the internal carotid and basilar arteries at baseline and in 
response to 5% CO2, and pseudo-continuous arterial spin labelling (PCASL) to measure 
regional cerebral blood flow. Blood pressures (automated cuff), heart rate (pulse oximeter), and 
end tidal CO2 (capnograph) were monitored throughout all acquisitions. See supplementary 
information for imaging parameters.  
 
Since poor cerebral vascular reactivity is linked to the risk of developing hypertension, we 
hypothesised that the hypertensive group would have impaired cerebral vascular reactivity. In a 
subgroup of participants, cerebral vascular reactivity to isoxic hypercapnia (5% CO2) and to a 
strong visual stimulus (flashing checkerboard20,  using a dual echo blood oxygen level 
dependent; BOLD and ASL MRI acquisition) was measured (supplementary material for MRI 
parameters). 
 
MRI analyses 
All data analyses were blinded and completed by separate investigators. Please see 
supplementary material for details regarding methodology for MRI analyses. In short we used 
automated brain segmentation (FAST; FSL, Oxford) to measure the volume of white matter, 
grey matter and cerebral spinal fluid. Angiogram analysis was completed in line with the 
methods used in the retrospective study. To measure blood flow in the right and left internal 
carotid and basilar arteries, phase contrast images were analysed using Segment (version 1.9, 
Medviso, Sweden)21.  Total cerebral blood flow was estimated as the sum of blood flow in these 
vessels and scaled for parenchymal tissue volumes. Cerebral vascular resistance was 
calculated as the brachial mean arterial pressure (measured during the phase contrast 
acquisition) divided by the average flow in each vessel. This method assumes that intra-cranial 
pressure and venous pressure is normal and similar between groups, and therefore that mean 
arterial pressure is an accurate estimation of cerebral perfusion pressure in different groups. 
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The method has been used in multiple studies to calculate cerebral vascular resistance 22, 23. 
Regional cerebral perfusion was measured from the PCASL images using the standard Buxton 
model 24. Cerebral vascular reactivity to hypercapnia (5% CO2) was calculated as the change in 
total cerebral blood flow (calculated as the sum of blood flow in the internal carotid and basilar 
arteries, measured using phase contrast MRI) from the normocapnic condition. Blood flow was 
scaled for changes in end tidal CO2 and blood pressure. Finally, positive and negative changes 
in cerebral blood flow and BOLD signal, in response to the flashing checkerboard stimulus, were 
measured in the visual cortex.  
 
Statistical analyses 
For sample size calculations pertaining to the case-control study, see supplementary material. 
All data analysis was blinded. An unpaired Students T-test was used to test for differences in 
participant’s characteristics/demographics between normotensive and hypertensive groups. A 
one-way ANCOVA was used to test for differences in total cerebral blood flow, regional cerebral 
blood flow and MSNA between hypertensive and normotensive groups, using BMI as a 
covariate.   Binary logistic regression was used to test for differences in the prevalence of 
anatomical variations (VAH, incomplete posterior CoW or VAH with an incomplete posterior 
CoW) between hypertensive and normotensive groups. To test for differences in cerebral blood 
flow and cerebral vascular resistance, between hypertensive and normotensive participants with 
and without anatomical variants, a one-way ANCOVA (BMI as a covariate) was used with a 
Bonferroni test for multiple comparisons. Participants sub-grouped into specific normotensive 
and hypertensive groups; a one-way ANCOVA (BMI as covariate) with a Bonferroni test for 
multiple comparisons was used to test for differences in demographics, blood pressures, 
cerebral blood flow, cerebral vascular resistance and MSNA.  
 
To predict which variables might be better predictors of hypertension (i.e. is cerebral vascular 
resistance a stronger predictor of hypertension than BMI?), conditional forward binary logistic 
regression was completed, where diagnosis of hypertension was the dependent variable. The 
independent variables were age, BMI, cerebral blood flow, cerebral vascular resistance, VAH 
plus an incomplete posterior CoW and MSNA. All statistical tests were two-tailed. Alpha was set 
at 0.05.  Where appropriate data are reported as mean ± SEM, median with interquartile range 
or as percentage with 95% confidence intervals. 
 
Results 
Retrospective study 
Anatomical variations in the cerebral vasculature 
Patient characteristics are outlined in the Supplementary Table 1.  Fishers exact test showed 
that VAH and an incomplete posterior CoW were highly prevalent in the hypertensive population 
(hypertensive vs. normotensive15, 18: 53% vs. 27% and 64% vs. 36% respectively; P<0.0001, 
Figure 1). The odds ratios indicated that individuals with VAH or those with an incomplete 
posterior CoW were 2.8 (95% CI; 1.8 to 4.3) and 3.1 (95% CI; 1.6 to 6.1) times more likely to 
have hypertension. There were no differences in the prevalence of an incomplete anterior CoW 
between our hypertensive cohort and that reported in a healthy control population18 (32% vs. 
25%, respectively, P=0.26). 
 
During the retrospective analysis we noted that there was also a high prevalence of VAH with 
an incomplete posterior CoW (27%). The prevalence of having both variants has not been 
compared in healthy controls previously. We were interested in whether the prevalence was 
higher in the hypertensive patients compared to controls, since having both may present further 
challenges to perfuse the posterior regions of the brain. These results prompted a case-control 
study where we assessed whether the anatomical variations in the posterior cerebral 
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vasculature related functionally to differences in cerebral perfusion and vascular resistance in 
hypertensive patients 
 
Case-control study 
Participant characteristics  
The hypertensive (n=77) and normotensive groups (n=49) were similar in age and height 
(P=0.12); however, body mass index (BMI) and body mass were lower in the normotensive 
group (P=0.02, Students T-test, Table 1). Office blood pressures, day-/night-time ambulatory 
blood pressures and MSNA were higher in the hypertensive compared to the normotensive 
group (P<0.0001, ANCOVA, Table 1). Hypertensive patients had a higher incidence of lacunar 
infarcts (14%) compared to normotensive patients (4%, P=0.03), but the number of subcortical 
and cortical infarcts were similar between groups (3% vs. 2%; P=0.680, and 1% vs. 1%; 
P=0.831, respectively, Fishers Exact Test). 
 
Anatomical variants in the posterior cerebral vasculature are more prevalent in humans with 
hypertension 
We observed that VAH, an incomplete posterior CoW and VAH with an incomplete posterior 
CoW were higher in hypertensive (57%, 60%, and 42%; analysed using MR angiography by 
blinded radiologist) compared to normotensive participants (Figure 1; 30%; P=0.006, 37%; 
P=0.028 and 19%; P=0.006; respectively, binary logistic regression). The odds ratio indicated 
that if VAH, an incomplete posterior CoW or VAH with an incomplete posterior CoW were 
present, then individuals were 3.0 (95% CI: 1.4 – 6.3), 2.6 (95% CI: 1.2 – 5.6) and 3.2 (95% CI: 
1.4-7.6) times more likely to have hypertension, respectively. Conditional forward binary logistic 
regression selected VAH as the strongest predictor of having a diagnosis of hypertension, when 
both VAH and an incomplete posterior CoW were inserted into the model. Importantly, there 
was no difference in the prevalence of an incomplete anterior CoW between hypertensive (25%) 
and normotensive (32%) groups (P=0.46).  Missing anterior communicating arteries were the 
main cause of an incomplete anterior CoW. The A1 segment of the anterior cerebral artery was 
missing in only a small proportion of individuals (left A1; 1% vs. 0%; P=1.00 and right A1; 4% vs. 
7%; P=0.45) in hypertensives and normotensives respectively). There was no difference in the 
prevalence of a combined incomplete posterior and anterior CoW between hypertensive and 
normotensive groups (27% vs. 20%, P=0.35). Finally, binary logistic regression indicated that 
there was no interaction between BMI and VAH (β= 0.016; P=0.234) or VAH plus an incomplete 
CoW (β= 0.018; P=0.77).  
 
Next, we determined whether these anatomical variants in the posterior cerebral circulation are 
functionally important.  Total arterial cerebral blood flow (measured using MR phase-contrast 
imaging) was lower in the hypertensive compared to the normotensive group (Table 1, 
P<0.0001; ANCOVA). Using region of interest analysis on cerebral perfusion maps (PCASL), 
cerebral perfusion was lower in the hypertensive compared to normotensive group in all regions 
studied (Table 3, P<0.05; ANCOVA). Moreover, total cerebral vascular resistance was higher in 
hypertensive participants versus those with normotension (P<0.0001; ANCOVA, Table 1). We 
hypothesised that VAH and/or an incomplete posterior CoW would be associated with lower 
cerebral perfusion.  
 
Participants were split into those with/without VAH (n=56/68, respectively) regardless of their 
blood pressure status. Those with VAH had a lower total arterial cerebral blood flow (P<0.0001, 
ANCOVA) and a higher cerebral vascular resistance (P<0.0001) than those without these 
anatomical variants (Figure 2). Data for both VAH and an incomplete posterior CoW showed 
similar differences and are presented in Figure 2. 
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Interestingly, hypertensive participants with VAH (n=39) had a lower cerebral arterial blood flow 
compared to hypertensives without VAH (n=36; Figure 2, P=0.014, one-way ANCOVA with 
Bonferroni test for multiple comparisons). Additionally, the reported incidence of lacunar type 
infarcts was greater in hypertensive patients with VAH versus those without VAH (22% vs. 3%, 
P=0.001, Fishers exact test). Intriguingly, there were no differences in cerebral blood flow 
(P=0.750) or cerebral vascular resistance (P=0.333) between the normotensive groups with and 
without VAH (ANCOVA and Bonferroni post-hoc test). This suggests that: a) in normotensive 
individuals, VAH was not associated with a higher cerebral vascular resistance and, b) that in 
the presence of VAH, individuals with normal blood pressure are able to maintain cerebral 
perfusion.  Importantly, we found that there was no difference in total cerebral blood flow and 
vascular resistance in hypertensive people with and without an incomplete anterior CoW 
(Supplementary Table 2). Additionally, there was no difference in these variables in 
hypertensives with or without both an incomplete anterior and posterior CoW (Supplementary 
Table 2). Similar findings are reported for the normotensive group. These data suggest that 
variants in the anterior CoW do not impact cerebral haemodynamics.  
 
The contralateral vertebral artery does not compensate for the hypoplastic artery in 
hypertensive patients 
Individuals with VAH usually have a larger contralateral vertebral artery, apparently 
compensating for the hypoplastic vessel 15. To estimate whether the contralateral vessel 
normalized blood flowing into the posterior circulation, we measured blood flow in the basilar 
artery (all data analysed with BMI as a covariate). In normotensive participants, there was no 
difference in blood flow in the basilar artery between those with/without VAH (11.4 ± 0.9 vs. 13.9 
± 0.9 mL/100mL/min, P=0.151; ANCOVA). In contrast, in the hypertensive patients there was a 
lower basilar blood flow with VAH compared to those without VAH (10.4 ± 0.9 vs. 13.4 ± 0.9 
ml/100mL/min, P=0.002). These data suggest that in participants with hypertension, the 
contralateral vertebral artery does not fully compensate for lower blood flow in the hypoplastic 
vertebral artery  
 
Assessing cause and effect: Cerebral vascular resistance, blood flow and muscle sympathetic 
nerve activity 
We next attempted to assess causality between cerebral vascular variants, cerebral 
hypoperfusion and the onset of elevated SNA, a driver of hypertension. To assess the temporal 
relationship between cerebral hypoperfusion and the onset of both increased sympathetic 
activity and hypertension, 4 sub-groups of patients with differing classes of hypertension were 
recruited and compared to age- and sex-matched normotensive controls. These groups were: 
borderline, untreated, treated-controlled, and treated but poorly controlled hypertensive 
participants (Table 2). The borderline (or high normal) group did not have hypertension but had 
daytime ambulatory SBP of 130-135 mmHg (Figure 3) and a high incidence of self-reported 
family history of hypertension in first order relatives (Table 2). The prevalence of family history 
of essential hypertension in all hypertensive groups was higher than that in the normotensive 
groups (Chi-square test, P<0.0001). Interestingly, the prevalence of VAH with an incomplete 
CoW was higher in the borderline hypertensive group compared to normotensive controls 
(borderline hypertension; 61%, and older normotension; 31%, Chi-squared test; P<0.05). 
 
Figure 3 shows that cerebral vascular resistance was elevated in the borderline hypertensive 
group compared to young and older normotensive controls. However, in the borderline group 
MSNA was not elevated and similar to the older normotensive group (49 ± 5 vs. 47 ± 3 
bursts/100 heart beats; ANCOVA; P=0.9). This suggests that increased cerebral vascular 
resistance occurs before the onset of higher MSNA and is thus a putative trigger for subsequent 
elevation of MSNA and blood pressure. Additionally, total cerebral blood flow was lower in the 
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borderline hypertensive group compared to older (P=0.002) and younger normotensive groups 
(P=0.001), but was similar to that in the uncontrolled hypertensive (P=1.00) and treated 
hypertensive groups (P=1.00). The total cerebral arterial blood flow in the untreated 
hypertensive group was similar to that in the older (P=0.891) and younger normotensive groups 
(P=0.899); suggesting that in the face of higher cerebral vascular resistance, the elevated 
resting blood pressure was able to normalise perfusion in this group.  
 
Is cerebral vascular resistance a good predictor of hypertension? 
Conditional forward binary logistic regression was completed to determine which variables were 
predictive of having a diagnosis of hypertension (n=126; treated controlled hypertensive group 
were included in the hypertension category). Cerebral vascular resistance was the strongest 
predictor of a diagnosis of high blood pressure (odds ratio 1.86, 95% CI: 1.44, 2.40, P<0.0001), 
followed by BMI (odds ratio 1.53, 95%CI: 1.23-1.92, P<0.0001), age (OR: 1.15, 95% CI: 1.04-
1.27, P=0.009) and total cerebral blood flow (OR: 1.23, 95%CI: 1.0-1.5, P=0.01). Thus, high 
cerebral vascular resistance predicts hypertension.  
 
Cerebrovascular vascular reactivity, hypertension and anatomical variants 
We found no difference in total cerebral vascular reactivity to CO2 (expressed as per % rise in 
end tidal CO2 and scaled for changes in mean arterial pressure; MAP) between the 
hypertensive (n=29) and normotensive groups (n = 22, 5.6 ± 0.6 vs. 4.5 ± 0.7 
mL/100mL/min/mmHg/%; P=0.21, ANCOVA, Supplementary Figure 1). Additionally, when the 
groups were split into participants with (n=19) and without VAH plus an incomplete CoW (n = 
32; split regardless of hypertensive status), there was no difference in cerebral blood flow 
reactivity to CO2 (4.7 ± 0.4 vs. 5.6 ± 0.7 mL/100mL/min/mmHg/%; P=0.41, Supplementary 
Figure 1).  
 
We next assessed the cerebral vascular reactivity to a strong visual stimulus (Figure 4A shows 
example acquisition). The visual stimulus caused a similar increase in cerebral blood flow in 
normotensive (n=28) and hypertensive (n=36) subgroups in an activation mask within the 
occipital lobe, consisting of a union of significantly activated voxels in the BOLD and ASL time-
series (Figure 4B). In all participants, negative BOLD and cerebral blood flow signals were also 
detected within the occipital lobe and surrounding the visual cortex (Figure 4, panel A for 
example of cerebral perfusion). Despite these similar changes in blood flow, the hypertensive 
group exhibited a greater increase in blood pressure during the visual stimulus (figure 4B, 
P=0.02, ANCOVA) suggesting that hypertensive men and women rely on increasing perfusion 
pressure to maintain cerebral blood flow than local vasodilatatory mechanisms. In a group with 
both VAH and an incomplete CoW, however, data indicated a difference in cerebrovascular 
reactivity. We found a blunted increase in BOLD signal along with a trend towards a blunted 
increase in cerebral blood flow response to the visual stimulus (Figure 4C). Moreover, linear 
regression analyses suggested that for participants with both VAH and an incomplete posterior 
CoW, the positive and negative BOLD responses have a stronger inverse relationship than for 
participants without VAH and incomplete posterior CoW (β1=-0.17; P<0.05 vs. β1 = 0.65; 
P<0.05, respectively; ANOVA, Supplementary Figure 2). This implies that for a larger positive 
increase in BOLD signal the hypertensive group rely on a blood flow steal from other adjacent 
tissue.  However, this needs to be interpreted with caution since the BOLD response is a result 
of neurovascular coupling 25, which is a mechanism that does not solely depend on regional 
cerebral blood flow. 
 
Discussion 
This is the first confirmation in conscious humans that the cerebral vasculature and cerebral 
hypoperfusion might be important in the development of hypertension. This is based on: 1) a 
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higher prevalence of congenital anatomical variants; VAH and an incomplete posterior CoW, in 
hypertensive patients that were associated with reduced cerebral blood flow and increased 
cerebral vascular resistance. 2) The association of these anatomical variants with diminished 
cerebrovascular reactivity in the visual cortex.  3) The finding of elevated cerebral vascular 
resistance before the increase in MSNA and hypertension. This was consistent with the finding 
that cerebral vascular resistance was found to be the greatest predictor of hypertension status 
compared to body mass index and age. 4) The reliance on a systemic blood pressure surge to 
increase cerebral blood flow, during a visual cortex stimulus, in the hypertensive cohort. Overall, 
these data support our contention that, in some cases, hypertension develops as ‘self-protection 
for the brain’.  
 
It is accepted that cerebral arteries and arterioles are remodelled in hypertension, thereby 
increasing resistance to blood flow 26. Narrowing of the vessel lumen and an increased 
wall/lumen ratio are typically demonstrated in animal models 8, 27, 28 and humans with 
hypertension 9, 29. Furthermore, cerebral blood flow is attenuated in elderly patients with 
hypertension 30, 31 and is related to white matter lesions32 and small vessel disease 33, a finding 
which is contradictory to studies indicating that cerebral autoregulation is intact in hypertensive 
patients 34. Our data are the first to show that in middle-aged hypertensive humans without 
cerebral stenotic disease, total arterial cerebral blood flow (Table 1) and cerebral perfusion in all 
brain regions measured (Table 3) are lower compared to age-matched normotensive 
participants. This may help to explain why patients with hypertension have an increased risk of 
developing vascular dementia 14. Traditionally, cerebral vessel remodelling and cerebral 
hypoperfusion were thought to be a consequence of high blood pressure. Evidence in animals 
and humans now suggest that this theory may be incorrect with the reverse true; cerebral artery 
remodelling and hypoperfusion may precede hypertension as found herein 10, 11. 
 
Remarkably, in this study, we show that cerebral vascular resistance is increased before the 
onset of sympathetic hyperactivity and hypertension in humans. Cerebral vascular resistance 
was elevated in a group of participants with borderline-high blood pressure (daytime SBP 130-
135 mmHg), as it was in all other hypertensive groups, whereas the level of SNA in the 
borderline population was similar to aged matched controls. A potential caveat of this study is 
the cross-sectional design; therefore we do not know whether the borderline hypertensive group 
will develop hypertension. A longitudinal study is needed to confirm this. Another potential 
limitation of this study is the indirect method used to calculate cerebral vascular resistance. 
Since measures of intracranial pressure were not possible, the method does not take into 
account potential variations in intracranial pressure between groups, and thus it’s influence on 
perfusion pressure and resistance. It is reasonable to assume that there was no difference in 
intracranial pressure between hypertensive and normotensive groups, since none of the 
participants showed symptoms of intracranial hypertension or hydrocephalus, and patients with 
tumours were removed from the study. Although many other studies have used this method of 
calculating cerebral vascular resistance22, 23, the method needs validating in both healthy 
controls and patients with disease. 
 
In the borderline hypertensive group, total arterial cerebral blood flow was lower than that in 
aged matched controls and the untreated hypertensive group, indicating that their blood 
pressure had not corrected for the reduction in cerebral perfusion. Since these participants have 
a similar self-reported family history to groups of hypertensive patients, they may represent a 
group of patients who have a high probability of developing hypertension in later life. 
Interestingly, the treated controlled hypertensive group had lower cerebral perfusion compared 
to the untreated group. This supports previous data, where anti-hypertensive treatment (except 
for angiotensin receptor blockers) was associated with a decline in cerebral blood flow and 
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parenchymal tissue volumes 35. Additionally, other studies indicate that in patients with 
hypertension, decreased mean arterial pressure occurred concomitantly with cognitive decline 
and increased Tau related neuro-degeneration 36. Therefore, although blood pressure lowering 
confers a reduced risk of a cardiovascular event37, it may also lower cerebral perfusion 
especially when cerebral artery hypoplasia and high cerebral vascular resistance exist. Our data 
emphasise the need to assess cerebral artery architecture and resistance to ensure that 
cerebral blood flow is not compromised when blood pressure is lowered. A failure to do so may 
put patients at risk of developing cognitive impairment and vascular dementia.  This is critical to 
consider following the results of the recent SPRINT trial, where intensive blood pressure 
lowering (target <120 mmHg) was shown to provide added protection against fatal and not fatal 
cardiovascular events 38. Conversely, lower target blood pressures (<120 mmHg) were 
associated with adverse events, such as syncope and orthostatic intolerance. Although trials, 
such as the SPRINT38 and Secondary Prevention of Small Subcortical Strokes39 indicate 
decreased incidence stroke with lower blood pressure targets (<120 and <130 mmHg, 
respectively), these changes were non-significant. The long-term effect of intensive blood 
pressure lowering on cognitive health and the rate of dementia has yet to be assessed. 
 
If cerebral hypoperfusion causes sympathoexcitation and hypertension then the brain must 
sense hypoxemia. The highly vascularized regions of the brainstem40 that regulate the 
autonomic control of blood pressure could potentially be such sites. In rodents, neurons in areas 
including the nucleus tractus solitarius and rostral ventrolateral medulla (RVLM) are directly 
sensitive to hypoxia and cause sympathoexcitation and augmented blood pressure 41 42. 
Moreover, Marina et al. 13 showed that hypoxia-induced activation of the RVLM in 
spontaneously hypertensive rats could be supressed by adenosine triphosphate antagonists or 
a glycogenesis inhibitor. These data indicate that metabolic by-products, which are increased 
during hypoxemia, can activate the neurons directly controlling sympathetic outflow.  
 
Exactly what causes elevated cerebral vascular resistance in hypertension is unclear. In the 
cerebral circulation, larger arteries predominantly regulate cerebral vascular resistance to blood 
flow, rather than the smaller arterioles 43, 44. Alterations in the structure of the large feeder 
arteries and collateral vessels are, therefore, likely contributors to increased cerebral vascular 
resistance predisposing individuals to hypertension.  For the first time, we present interesting 
evidence that the prevalence of congenital cerebral variants confined to the posterior circulation 
(VAH and an incomplete posterior CoW) is greater in hypertensive patients compared to 
controls. This supports the concept proposed by Dickinson 9, that vertebral artery narrowing  
triggers brainstem hypoperfusion and hypertension. We report that hypertensive participants 
with VAH (and those with both VAH plus an incomplete posterior CoW) had lower cerebral 
perfusion and elevated cerebral vascular resistance. VAH and an incomplete posterior CoW 
have both been individually linked to increased risk of posterior territory stroke 45 46 and may 
provide an explanation as to why hypertension is a specific risk factor for posterior circulation 
infarcts 47. We show that VAH is linked to a higher proportion of lacunar type infarcts in our 
cohort of hypertensive patients. Additionally, congenital variants in the cerebral circulation may 
help to explain a proportion of the estimated inheritance of hypertension (30-68% 4). However, if 
these variants are indeed congenital, then it is perplexing why hypertension develops with age 
rather than during childhood development. Potentially, VAH and/or an incomplete posterior CoW 
might predispose individuals to cerebrovascular disease, since these smaller vessels may be 
prone to pro-thrombotic/atherosclerotic damage, increasing the risk of stenosis or occlusion in 
the hypoplastic vessel15. However, this needs further research. Intriguingly, we show that 
normotensive patients who exhibit these anatomical variants do not have elevated cerebral 
vascular resistance, and have a normal cerebral perfusion suggesting adequate remodelling 
has compensated.   Exactly what prevents an increase in cerebral vascular resistance in these 
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patients is unclear but may include: compensation from the other vertebral artery, collateral 
vessel formation to maintain cerebral perfusion and/or lower rates of cerebral atherosclerotic 
disease. The exact mechanism(s) might provide therapeutic insight. 
 
In hypertensive patients without VAH, cerebral blood flow remained lower than that measured in 
aged matched normotensives with normal vertebral anatomy. This might be explained by the 
increased incidence of cerebral small vessel disease in hypertension, which may develop before 
the onset of high blood pressure 33. Although basal blood flow is important, cerebral vascular 
reactivity to changes in metabolic demand are also crucial for cerebral health and is impacted 
by cerebral vessel disease. We used a visual task to assess regional changes in cerebral blood 
flow in hypertensives and normotensives. Whilst there were no differences in blood flow 
responses between groups in the occipital lobe, the hypertensives had a greater systemic blood 
pressure response during the challenge. This suggests that the increased blood flow was driven 
by the elevation of blood pressure in the hypertensive group.  These data support our ‘selfish 
brain hypothesis’: generation of hypertension to satiate the brain.  
 
We propose that the level of cerebral arterial resistance could be used as a novel prognostic 
indicator of those who will become hypertensive, and might be a valuable diagnostic marker to 
stratify treatment. However, a longitudinal study is needed to confirm this. For example, 
borderline hypertensive patients with elevated cerebrovascular resistance may benefit from 
early treatment with specific anti-hypertensive therapies that prevent further vessel remodelling 
and are known to improve cerebral blood flow (e.g. angiotensin converting enzyme inhibitors 48 
or angiotensin receptor blockers 35), although this requires further investigation. Future research 
focused on screening for hypoplastic vertebral arteries (particularly genetic variants 4) may also 
be advantageous to better direct anti-hypertensive treatment, as VAH could add complication in 
treating high blood pressure whilst preventing cerebral hypoperfusion and early onset dementia. 
 
In summary, we show that congenital cerebrovascular variants, elevated cerebral vascular 
resistance and cerebral hypoperfusion are associated with the development of hypertension in 
humans. Due to the cross-sectional design of this study, further longitudinal based research is 
required to confirm that high cerebral vascular resistance and congenital cerebral vascular 
variants are causal in the onset of hypertension in humans. Once this mechanism is confirmed, 
cerebrovascular architecture should potentially be considered in the prognosis, diagnosis and 
treatment of hypertension. Early treatment to prevent further vascular remodelling might help to 
prevent both the progression of hypertension but also vascular dementia. 
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Table 1: Characteristics of participants in the case-control study. 
 Normotensive (n=49) Hypertensive (n=77) 
Female sex (%) 57  58 
Age (years) 52 ± 2 57 ± 2 
Height (cm) 171 ± 1 172 ± 1 
Weight (kg) 71 ± 2 82 ± 2 
Body mass index (kg/m2) 25.2 ± 0.8 27.7 ± 0.5 *** 
Office                   SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
122 ± 2 
75 ± 1 
91 ± 1 
65 ± 2 
148 ± 2 **** 
89 ± 2 **** 
109 ± 2 **** 
66 ± 1 
ABPM daytime     SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
119 ± 2 
76 ± 1 
90 ± 1 
75 ± 2 
139 ± 2 **** 
85 ± 2 **** 
101 ± 2 **** 
74 ± 1 
ABPM night          SBP (mmHg) 
                             DBP 
                             MBP 
                             HR (beats/min) 
107 ± 2 
64 ± 1 
79 ± 1 
65 ± 2 
122 ± 2 **** 
72 ± 1 **** 
89 ± 1 **** 
64 ± 1 
Anti-hypertensive medications (#) 0  1 (0 – 6) 
ACEi (%) 
ARB (%) 
CCB (%) 
Diuretic (%) 
β-blocker (%) 
α-blocker (%) 
I1-blocker (%) 
0 
0 
0 
0 
0 
0 
0 
23 
15 
20 
19 
8 
2 
2 
Family history of hypertension (%) 17  48††† 
Brain volumes 
White matter (%) 
Grey matter (%) 
Grey/white matter ratio 
 
38.61 
40.49 
1.05 
 
38.33 
41.74 ** 
1.09 ** 
Total CBF (ml/min/100 mL tissue) 54.4 ± 1.1 61.8 ± 1.4 **** 
Total CVR (ml/min/100mL/mmHg) 1.91 ± 0.05 1.28 ± 0.03 **** 
SBP; systolic blood pressure, DBP; diastolic BP, MBP; mean blood pressure, HR; heart 
rate, ABPM; ambulatory blood pressure monitoring, ACEi; angiotensin converting 
enzyme inhibitor, ARB; angiotensin receptor blocker, CCB; calcium channel blocker, 
CBF; cerebral blood flow, CVR; cerebral vascular resistance. Family history of 
hypertension in first order relatives is self-reported. Data are mean ± SEM or median 
(IQR). *** P<0.001 (unpaired Students T-test), ** P<0.01 **** P<0.0001 (One-way 
ANCOVA, BMI as covariate). ††† P<0.001; Fisher’s exact test. 
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Table 2: Characteristics of normotensive (NTN) and hypertensive (HTN) sub-groups.  
 Young-NTN 
(n=20) 
Older-NTN 
(n=28) 
Borderline-HTN 
(n=20) 
Untreated-HTN 
(n=20) 
Treated-HTN 
(n=19) 
Uncontrolled-HTN 
(n=18) 
Age (years) 28 ± 0.8 52 ± 2 * 51 ± 3 * 56 ± 2 * 58 ± 2 * 59 ± 2 * 
Sex (% women) 50 50 45 50 55 46 
BMI (kg/m2) 24.0 ± 0.8 24.5 ± 0.6 28.3 ± 1.1 * † 28.0± 1.2 28.7 ± 1.0 *† 31.0 ± 0.9 *† 
Office                   
SBP (mmHg)                           
DBP                           
MBP                         
HR (beats/min) 
 
121 ± 3 
73 ± 2 
89 ± 2 
67 ± 3 
 
123 ± 2 
76 ± 1 
92 ± 1 
64 ± 2 
 
138 ± 2* 
84 ± 2 
103 ± 1 
64 ± 2 
 
169 ± 5 *†‡§ 
99 ± 3*†‡§ 
122 ± 4 *†‡§ 
67 ± 2 
 
138 ± 3 
82 ± 2 
102 ± 2 
68 ± 3 
 
163 ± 5 *†‡§ 
93 ± 2 *†‡§ 
116 ± 3  *†‡§ 
68 ± 3 
ABPM daytime      
SBP (mmHg) 
DBP                       
MBP                         
HR (beats/min) 
 
121 ± 2 
78 ± 2 
90 ± 2 
77 ± 3 
 
118 ± 2 
76 ± 1 
90 ± 1 
74 ± 2 
 
132 ± 2 *† 
82 ± 1† 
97 ± 2*† 
72 ± 2 
 
150 ± 4 *†‡§ 
93 ± 3  *†‡§ 
111 ± 3 *†‡§ 
76 ± 2 
 
127 ± 2  
80 ± 2 
95 ± 1 
76 ± 2 
 
146 ± 2 *†‡§ 
88 ± 2 *†‡§ 
106 ± 2  *†‡§ 
70 ± 3 
ABPM night          
SBP (mmHg)                         
DBP                           
MBP                         
HR (beats/min) 
 
114 ± 3 
66 ± 3 
82 ± 3 
68 ± 4 
 
105 ± 2 
63 ± 1 
78 ± 1 
64 ± 2  
 
118 ± 2*† 
70 ± 2† 
86 ± 2† 
64 ± 2 
 
126 ± 3*†‡§ 
76 ± 2*† 
93 ± 2*† 
65 ± 2 
 
115 ± 2 
70 ± 2 
84 ± 2 
76 ± 2 
 
128 ± 3  *†‡§ 
74 ± 2† 
90 ± 4*† 
63 ± 3 
Anti-hypertensive 
medications (#) 
0 0 0 0 2.0 (1.0-2.0) 3.0 (1.5 – 2.5) 
ACEi (%) 
ARB (%) 
CCB (%) 
Diuretic (%) 
β-blocker (%) 
α-blocker (%) 
I1-blocker (%) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
42 
32 
26 
42 
16 
0 
5 
63 
37 
63 
47 
21 
11 
5 
Family history HTN (%) 5 22 55 † 59 † 58 † 56 † 
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See Table 1 for abbreviations. Data are mean ± SEM or median (IQR). * P<0.05 vs. young-NTN, † P<0.05 vs. older-NTN, ‡P<0.05 vs. 
borderline-HTN, § P<0.05 vs. treated-HTN (One-way ANCOVA with Bonferroni test for multiple comparisons, or chi-square test where 
appropriate).  
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Table 3: Regional (bi-lateral) cerebral perfusion in hypertensive compared to 
normotensive humans included in the case-control study  
Regional perfusion 
(mL/100g/min) 
Hypertension Normotension P-value 
Brainstem  25.7 ± 0.7 29.1 ± 0.9 0.003 
Cerebellum 34.1 ± 1.1 42.2 ± 1.3  <0.0001 
Pons  25.3 ± 0.7 27.9 ± 0.9  0.022 
Medulla 25.9 ± 1.0 22.7 ± 0.7 0.006 
Midbrain 28.9 ± 1.0 34.8 ± 1.3 0.001 
Insula 46.1 ± 1.2  54.4 ± 1.2  <0.0001 
Thalamus 39.6 ± 1.2 46.7 ± 1.2 <0.0001 
Occipital pole 37.3 ± 1.7 50.0 ± 2.1 <0.0001 
Frontal pole 38.1 ± 1.2 45.6 ± 1.5 <0.0001 
Precentral gyrus 37.7 ± 1.1 44.7 ± 1.4 <0.0001 
Anterior cingulate cortex 49.2 ± 1.1 57.2 ± 1.6  <0.0001 
Temporal pole  34.6 ± 1.0 40.6 ± 1.2 <0.0001 
P-values represent one-way analysis of covariance with body mass index as a covariate 
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Figures 
 
Figure 1:  Congenital variants of the posterior cerebral circulation are more prevalent in people with hypertension 
compared to normotensive controls. A and B: examples vertebral artery hypoplasia (VAH; right image) and an incomplete 
posterior circle of Willis (iCoW; no posterior communicating arteries; pCoA; right image). C: (retrospective study, n=133) 
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prevalence of VAH and iCoW is higher in patients with hypertension compared to the prevalence in controls. There were no 
differences in age (51 ± 2 vs. 51 ± 2 years, p=0.93), sex (males; 56% vs. 50%, p=0.50), systolic blood pressure (SBP; 169 ± 3 vs. 
170.1± 3 mmHg, p=0.87) or diastolic blood pressure (DBP; 97 ± 2 vs. 96 ± 5 mmHg, p=0.72) between the hypertensive patients with 
VAH and those without this anatomical variant. D: (case-control study, n=136) prevalence of VAH and VAH with an incomplete 
posterior CoW in hypertensives and normotensive controls. The retrospective study is compared to data previously described by 
Park et al15. ** P=0.006 (binary logistic regression), ****P<0.0001 (Fishers exact test).  
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Figure 2: vertebral artery hypoplasia (VAH) or VAH that co-exists with an incomplete circle of Willis (iCoW) are linked with 
lower cerebral blood flow (CBF) and elevated cerebral vascular resistance (CVR). A and B:  total CBF and CVR estimated via 
phase contrast imaging in participants with (n=56) and without (n=68) VAH. C and D:  total CBF and CVR in participants with VAH 
plus an incomplete posterior circle of Willis (VAH+iCoW; n=42) or without this anatomical variant (n=82). E and F: CBF and CVR in 
those with/without VAH split in hypertensive (HTN) or normotensive (NTN) groups. G and H: similar data to E and F but grouped by 
incidence of VAH+iCoW. Groups with VAH or VAH+iCoW had a higher CVR and a lower CBF compared to those without these 
variants. Data are mean ± SEM. **** P<0.0001 (one-way ANCOVA with BMI as covariate and Bonferroni for multiple comparisons), * 
P<0.05, ***P<0.001 (one-way ANCOVA with BMI as covariate and Bonferroni for multiple comparisons). I to L: examples of 3-D 
blood velocity pixel maps in a cross section of the left and right vertebral arteries (LVA; RVA), from a normotensive and hypertensive 
volunteer without VAH (NoVAH) and with VAH (+VAH). Each large square represents a time point in the cardiac cycle starting with 
peak systole. Velocity maps for nine successive time points within a cardiac cycle are shown in participants. In these examples, a 
negative velocity (blue to orange) represents blood travelling in a direction towards the brain (anterograde flow). Flow velocity is 
clearly lower in hypoplastic vessels, but in hypertensive patients the contralateral vessel does not correct for this as it does in 
normotensive controls.  
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Figure 3: Cerebral vascular resistance (CVR) is elevated before an increased muscle sympathetic nerve (MSNA) activity in 
patients with borderline hypertension. A: total CVR and muscle MSNA in young normotensive (yNTN), older NTN (oNTN), 
borderline hypertensive (bHTN), untreated HTN (uHTN), treated but poorly controlled HTN (pcHTN) and treated controlled HTN 
(tHTN) participants. B:  total cerebral blood flow (CBF) in the 6 different groups. C: examples of multi-unit MSNA recordings in the 6 
different groups. The blue recordings represent integrated bursts of MSNA measured directly from the peroneal nerve, which are 
cardiac synchronous and coupled to the arterial pressure waveform shown below in pink. * P<0.05 vs. young NTN, † P<0.05 vs. older 
NTN (one-way ANCOVA with BMI as covariate and Bonferroni for multiple comparisons).  
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Figure 4: Cerebrovascular reactivity in the visual cortex is maintained in patients with hypertension due to a systemic 
pressor response, which does not occur in normotensive controls. A: example BOLD signal change during a visual (flashing 
checker-board) stimulus in a patient with a normal posterior cerebral circulation (left) and patient with vertebral artery hypoplasia 
(VAH) plus an incomplete posterior circle of Willis (iCoW, right). B: average positive and negative BOLD (left), cerebral blood flow   
(CBF; middle), and mean arterial pressure (MAP; right) responses to visual stimulus (flashing checker-board) in participants with 
normotension and hypertension. The data indicate that there was no difference in cerebral reactivity to the visual stimulus in 
hypertensive and normotensive patients; however, the hypertensive group had a greater BP response to the stimulus (ANCOVA, BMI 
as covariate). C: CBF and BOLD responses to the visual stimulus in patients grouped by their posterior anatomy variants (those with 
or without VAH+iCoW. When split into groups by cerebral anatomy variants, participants with VAH+iCoW had a lower cerebral 
vascular reactivity (lower BOLD signal change) than those without VAH+iCoW. In the VAH+iCoW group there was only a trend 
towards a greater blood pressure response to the visual stimulus (Mann-Whitney test). Notably, all participants had a negative BOLD 
and cerebral blood flow response to visual stimulus in some brain voxels, which is associated with a blood flow steal to increase flow 
to more metabolic active regions 49. In the hypertensive participants, stealing blood flow from tissue that is already hypoperfused may 
put this tissue at risk of becoming ischemic.  
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Novelty and significance 
What is known? 
 Cerebral arterial remodelling occurs in humans with hypertension and animal 
models of hypertension. 
 Experimental animal models of hypertension indicate that cerebral vascular 
remodelling occurs before the onset of hypertension. 
What new information does this article contribute?  
 Hypertension is more common in people with congenital cerebrovascular 
anatomical variants (i.e. vertebral artery hypoplasia). 
 These anatomical variants were associated with lower cerebral perfusion, 
especially in hypertensive patients. 
 Vertebral artery hypoplasia was more prevalent in people with high-normal blood 
pressure (who had an elevated family history of hypertension) compared to a 
normotensive cohort. 
 Cerebral hypoperfusion appears to occur before the onset of elevated 
sympathetic nerve activity and the onset of hypertension and thus may be causal 
in the onset of the disease.  
Summary  
Data from animal models of hypertension indicate that hypertension may develop as a 
vital mechanism to maintain adequate blood flow to the brain. In this study we 
investigated whether this mechanism is involved in the aetiology of human hypertension. 
Using magnetic resonance imaging we reveal that there is a higher prevalence of 
congenital cerebral vascular variants in patients with hypertension compared to healthy 
controls. We found that the majority of hypertensive patients exhibited vertebral artery 
hypoplasia and missing or hypoplastic posterior communicating arteries. This resulted in 
increased cerebrovascular resistance and hypoperfusion of the brain. This novel finding 
became more revealing when, surprisingly; we found that the cerebral artery variants, 
high cerebrovascular resistance and cerebral hypoperfusion were already present in 
patients with high-normal blood pressure (but with a strong family history of 
hypertension). This suggests that they were not caused by high blood pressure and may 
be causal in the development of hypertension. Additionally, untreated hypertensive 
patients had normal cerebral blood flow, but those on treatment (with normal blood 
pressure) had reduced cerebral perfusion. Our data may have novel prognostic and 
diagnostic importance; potentially patients with congenital cerebral hypoplasia are at risk 
of developing hypertension. Moreover, the data caution against aggressive lowering of 
blood pressure without checking cerebral perfusion adequacy.  
 
 
 
